![]() Introduction to Quantum Mechanics (2nd edn) by D.Principles of Quantum Mechanics (2nd edn), by R.Introductory Quantum Mechanics (4th edn), by R.Cheap Indian editions of most of these books are available. I am listing quite a few textbooks below, and it will be good if you have a personal copy of at least one of these. Most of the textbooks cover the topics mentioned above quite nicely. We are fortunate that a large number of excellent textbooks have been written on this subject. Angular momentum operators and their commutation relations. Spherically symmetric potentials and angular momentum in quantum mechanics. ![]() Creation and annihilation operator approach to the simple harmonic oscillator.Applications of the postulates of quantum mechanics to spin- 1 2 and two-level systems.Postulates of quantum mechanics and their physical interpretation.Mathematical tools of quantum mechanics.Exactly solvable problems in quantum mechanics: solving the Schrdinger equation for the simple harmonic oscillator and hydrogen atom.Discussion of a wave packet for the free particle case. Solution of the Schrdinger equation for simple cases such as: (a) free particle, (b) potential barriers, (c) potential wells etc. Born interpretation of the wave function. Wave function and Schrdinger equation.Young's double slit experiment with electrons and photons and other experiments. Why quantum mechanics? Louie de Broglie's hypothesis and wave-particle duality. ![]() I plan to cover the following topics during the semester: Combine this with frequency increases, increased memory bandwidth, architectural improvements, and around the same power and we land at the +50 perf/watt number AMD cited. Apart from that, no other prior background will be assumed. So in reality the 7900 XTX has 6144 'gaming shaders' compared to the 69. I will assume that you have some knowledge of partial differential equations and basics of linear algebra. This story has been updated to clarify Relyvrio's approval status.This course is all about an introduction to quantum mechanics. However, regulators need to balance this desire against potential harms, and tofersen is not without risks: 7% of patients on the drug had serious neurologic adverse events. Given the fast-moving nature of ALS, and Sod1 ALS in particular, it is understandable that patients want new drugs fast. Bulls will also point to open-label extension data suggesting stabilisation of disease. ![]() However, Biogen and Ionis pressed on with a filing for accelerated approval based on reductions in neurofilament light chain. Tofersen’s fate should have been sealed after it flunked the Valor study. However, the panel could help gauge sentiment at the FDA’s neuroscience division following the departure of its erstwhile chief Billy Dunn, who had been a champion of controversial drugs including Relyvrio. The verdict, and the agency’s eventual decision on approvability, will not be needle-moving for the companies: SVB Securities' analysts expect peak sales of just $300m. That project is approaching judgement day, with an FDA adcom scheduled for 22 March. In the long term, Amylyx expects around 10,000 patients to be on Relyvrio at any given time.Īnother ALS contender, Biogen and Ionis’s tofersen, is aimed at a much smaller niche: disease caused by Sod1 mutations, which affect around 300 patients in the US. Still, it is hard to see Relyvrio being pulled, particularly if demand stays strong in a disease with so few options. A survival analysis, which will likely be used as the barometer for success, is not due for a further year. The group has plenty of breathing space: initial results are due mid-2024 but the focus then will be on functional data. Will the good times continue? Amylyx execs famously promised to withdraw Relyvrio if the ongoing confirmatory Phoenix trial fails. He expects Amylyx to come close to breakeven next quarter, which would be an impressive feat so soon after launch. This was well ahead of expectations that had already been boosted by a promise of higher-than-expected demand last month – setting Relyvrio up for blockbuster revenues, if Amylyx can keep it on the market.ġ,300 patients were on Relyvrio by the end of last year, and the group expects to double this in the first quarter – an estimate that Evercore ISI’s Umer Raffat believes could be conservative. The group’s stock climbed 16% this morning after fourth-quarter sales of the product, which was launched in the US in October, totalled $22m. Small companies tend to run into problems when launching new drugs, so it is no wonder that investors were pleasantly surprised by strong early numbers for Amylyx’s amyotrophic lateral sclerosis therapy Relyvrio.
0 Comments
Leave a Reply. |